Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
90 participants
OBSERVATIONAL
2017-01-31
2018-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Metabolomic analysis of serum, plasma and urine has revealed panels of metabolites that distinguish patients with cardiovascular disease, breast cancer, Parkinson disease, Alzheimer's disease and diabetes from control patients. Regarding ocular diseases only few studies have been published, related to diabetic retinopathy, retinal detachment, age-related macular degeneration, uveitis and glaucoma.
Glaucoma is one of the leading causes of blindness in the world, according to the World Health Organization, and there are still no biomarkers that can provide an early diagnosis. Nowadays, glaucoma classification relies substantially in the measurement of intraocular pressure (IOP), which can be rather artificial and also unreliable since IOP values can fluctuate during the day. Moreover, patients with normal IOP values can also develop glaucomatous neuropathy (normal-tension glaucoma, NTG) and progress even when IOP is decreased. Several studies have shown that NTG patients suffer from a systemic vascular dysregulation, with higher rates of systemic hypotension, Raynaud phenomenon and migraine. Hence, other mechanisms than an increased IOP are of importance in the development and progression of glaucoma.
Only one metabolome-wide study has been made in glaucoma (Burgess, I.; 2015). In a sample of 72 american patients with primary open angle glaucoma (POAG), the authors found significant differences in comparison to controls.
The hypothesis for this study is that glaucoma patients will differ from controls, and POAG patients will differ from NTG patients. The investigators will look into metabolomics as a way to create a method to diagnose and stratify patients, as an add-on or alternative to the currently available diagnostic tools like IOP, functional and structural measurement.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Validation of Retinal Oximetry in Glaucoma Patients: a Structural and Functional Correlation
NCT01391247
A Real-World Study of Interventional Clinical Outcomes in Patients With Open Angle Glaucoma and Other Chronic Eye Diseases
NCT07216677
mRNA Expression in Lymphocytes of Glaucoma Patients
NCT00327509
Ultrastructural Changes of Trabeculectomy Specimens in Patients With Uveitic Secondary Glaucoma
NCT00917670
Assessing Ocular Hemodynamic Response to Surgical Intervention in Glaucoma
NCT02891317
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
POAG
Primary open angle glaucoma patients
Metabolomics analysis of patient samples
Metabolomics analysis of patient samples by mass spectrometry and nuclear magnetic resonance spectroscopy.
NTG
Normal/Low tension glaucoma patients
Metabolomics analysis of patient samples
Metabolomics analysis of patient samples by mass spectrometry and nuclear magnetic resonance spectroscopy.
Control
Patients with cataract and without glaucoma or other eye diseases
Metabolomics analysis of patient samples
Metabolomics analysis of patient samples by mass spectrometry and nuclear magnetic resonance spectroscopy.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Metabolomics analysis of patient samples
Metabolomics analysis of patient samples by mass spectrometry and nuclear magnetic resonance spectroscopy.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Controls (non glaucoma): undergoing cataract surgery
* Caucasian
Exclusion Criteria
* any intra ocular surgery on study eye, other than clear cornea cataract surgery more than one year before
* other eye pathologies than the one the surgery is intended for (except refractive error and cataract in glaucoma patients), namely retinopathies, uveitis and other causes for neuropathy.
60 Years
90 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
FRO (Funds for Research in Ophthalmology, Belgium)
UNKNOWN
Universitaire Ziekenhuizen KU Leuven
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Prof. Dr. Stalmans Ingeborg
Head of the glaucoma department
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ingeborg Stalmans, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Universitaire Ziekenhuizen KU Leuven
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospitals Leuven
Leuven, Leuven, Belgium
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Sien Boons
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MISO Study
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.